SuperworthAbbVie Inc. ABBV
Drug Manufacturers - General, Healthcare
$270.25
−0.41%
- Market cap
- $477.6B
- PE
- 76.7×
- 10y median 27.5×
- Forward PE
- Price to sales
- 7.4×
- EV/EBIT
- 26.0×
- Revenue, 12 months
- $64.4B
- +10% on a year ago
- Net margin
- 9.8%
- Free cash flow yield
- 3.8%
AbbVie trades at 76.7× trailing earnings, pricier than 86% of the last ten years. Revenue was $64.4B over the last twelve months, up 10% on a year earlier with a 10% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $14.3B | $12.3B | $14.5B | $14.5B | $15.1B+6% | $13.3B+8% | $15.4B+7% | $15.8B+9% | $16.6B+10% | $15B+12% | $17B+10% | |
| Cost of revenue | $5.7B | $4.1B | $4.2B | $4.2B | $4.4B−23% | $4B−2% | $4.3B+3% | $5.3B+26% | $4.6B+4% | $4.2B+5% | $4.3B−1% |
| Gross profit | $8.6B | $8.2B | $10.3B | $10.2B | $10.7B+25% | $9.3B+14% | $11.1B+8% | $10.5B+2% | $12.1B+13% | $10.8B+15% | $12.7B+15% |
| R&D | $1.9B | $1.9B | $1.9B | $2.1B | $6.8B+252% | $2.1B+7% | $2.1B+9% | $2.3B+9% | $2.6B−62% | $2.5B+20% | $2.3B+10% |
| SG&A | $3.2B | $3.3B | $3.4B | $4.2B | $3.9B+21% | $3.3B−1% | $3.3B−4% | $3.6B−15% | $3.9B+1% | $3.6B+9% | $3.6B+12% |
| $3.2B | $2.8B | $4B | $3.8B | −$1.5B | $3.7B+33% | $4.9B+22% | $1.9B−50% | $4.5B | $4B+7% | $6.4B+31% | |
| Interest expense | $564M | $660M | $726M | $720M | $702M+25% | $700M+6% | $740M+2% | $739M+3% | $714M+2% | $717M+2% | $746M+1% |
| Pre-tax income | $1.2B | $1.8B | $2.1B | $2.1B | −$2.3B | $1.7B−5% | $1.6B−28% | $714M−66% | $2.7B | $1B−37% | $4.3B+175% |
| $388M | $383M | $773M | $520M | −$2.2B | $372M−3% | $613M−21% | $526M+1% | $853M | $342M−8% | $662M+8% | |
| Net income | $822M | $1.4B | $1.4B | $1.6B | −$22M | $1.3B−6% | $938M−32% | $186M−88% | $1.8B | $695M−46% | $3.6B+285% |
| $0.46 | $0.77 | $0.77 | $0.88 | −$0.02 | $0.72−7% | $0.52−33% | $0.10−89% | $1.02 | $0.39−46% | $2.03+290% | |
| 1.8B | 1.8B | 1.8B | 1.8B | 1.8B+0% | 1.8B−0% | 1.8B+0% | 1.8B+0% | 1.8B+0% | 1.8B+0% | 1.8B+0% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times AbbVie's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ABBVAbbVie Inc. | $477.6B | 76.7× | 27.5× | 7.4× | +10% | 9.8% | |
| JNJJohnson & Johnson | $615.8B | 29.9× | 24.2× | 6.4× | +8% | 21.5% | |
| MRKMerck & Co., Inc. | $348.2B | 114× | 25.7× | 5.3× | +5% | 4.8% | |
| AMGNAmgen Inc. | $219.7B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| LLYEli Lilly and Company | $1.1T | 39.9× | 41.3× | 14.0× | +50% | 33.5% | |
| PFEPfizer Inc. | $158.5B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| BMYBristol-Myers Squibb Company | $121.5B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| Peer median | $283.9B | 33.4× | 22.6× | 5.6× | +6% | 20.2% |
About
- Chief executive
- Rob Michael, since 2024Longtime Abbott and AbbVie finance executive, CEO since 2024. Source
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .